Conditions: Malignant Melanoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 7
Healthy volunteers: no

Brief summary:
This open-label, non-randomized study will assess the mass balance, metabolism, routes and rates of elimination as well as efficacy and safety of RO5185426 (RG7204; PLEXXIKON; PLX4032) in previously treated or untreated patients with metastatic melanoma. Patients will receive continuous twice daily oral treatment with RO5185426. On Day 15, a 14C-labeled dose will be administered. Anticipated time on study treatment is until disease progression occurs.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: RO5185426
Intervention descriptions: intervention 1: Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered

Protocol document: